Depomed Will Cease All Spending on Sefelsa

Depomed, Inc.

, a specialty pharmaceutical company, announced today that the Reproductive Health Drugs Advisory Committee (RHDAC) of the U.S. Food and Drug Administration (FDA) voted 2-12 against approval for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin,^ to treat moderate to severe vasomotor symptoms due to menopause.  SEFELSA is the proposed trade name for the medication and was formerly referred to as Serada.  Based on the outcome of committee meeting, the company will not have a conference call today as previously indicated.